Factor Xa-driven thrombin generation in plasma: Dependency on the aminophospholipid density of membranes and inhibition by phospholipid-binding proteins

Summary

Phosphatidylserine (PS) externalization of activated platelets plays a pivotal role in haemostasis and thrombosis. In the present study we have explored the relationship between the PS density of membranes and the rate of thrombin generation in plasma. Factor (F)Xa-initiated thrombin generation was measured in platelet-free plasma (PFP) containing either phospholipid vesicles of varying PS-content or non-stimulated platelets (reconstituted PRP). The duration of the initiation phase of FXa-driven thrombin generation decreased dramatically with increasing PS density. Concomitantly, the maximal rate of thrombin generation during the propagation phase (maxR) increased non-linearly, with the steepest incline between 5 and 10 mol% PS. Titration of FVa into plasma containing 2 mol% PS increased maxR proportionally and diminished the lag phase. In contrast, platelet-dependent thrombin generation was not influenced by addition of FVa. With increasing platelet concentration, the duration of the initiation phase drastically decreased, and maxR increased proportionally. At a physiologically relevant platelet concentration, maxR corresponded with the maxR found with 2 µM of 10 mol% PS. Annexin A5 (AnxA5) and lactadherin appeared to be powerful inhibitors of in-situ thrombin generation under all conditions examined, with AnxA5 being three- to fourfold more potent than lactadherin. In conclusion, maximal thrombin generation in plasma requires membranes with a density of 10–20 mol% PS. Our data further indicate that thrombin formed in situ induces externalization of PS to approx 10 mol% in a substantial platelet subpopulation.

Keywords

Platelet physiology - thrombin - phospholipids - coagulation factors - annexins

• References

• 1 Bode W. Structure and interaction modes of thrombin. Blood Cells Mol Dis 2006; 36: 122-130.
• 2 Mann KG, Brummel-Ziedins K, Orfeo T. et al. Models of blood coagulation. Blood Cells Mol Dis 2006; 36: 108-117.
• 3 Weiss HJ. Scott syndrome: a disorder of platelet coagulant activity. Seminars in hematology 1994; 31: 312-319.
• 4 Toti F, Satta N, Fressinaud E. et al. Scott syndrome, characterized by impaired transmembrane migration of procoagulant phosphatidylserine and hemorrhagic complications, is an inherited disorder. Blood 1996; 87: 1409-1415.
• 5 Dachary-Prigent J, Freyssinet JM, Pasquet JM. et al. Annexin-V as a probe of aminophospholipid exposure and platelet membrane vesiculation – a flow cytometry study showing a role for free sulfhydryl groups. Blood 1993; 81: 2554-2565.
• 6 London FS, Marcinkiewicz M, Walsh PN. A subpopulation of platelets responds to thrombin- or SFLLRN-stimulation with binding sites for factor IXa. J Biol Chem 2004; 279: 19854-19859.
• 7 Keuren JFW, Wielders SJH, Ulrichts H. et al. Synergistic effect of thrombin on collagen-induced platelet procoagulant activity is mediated through protease-activated receptor-1. Arterioscler Thromb Vasc Biol 2005; 25: 1499-1505.
• 8 Wolfs JLN, Comfurius P, Rasmussen JT. et al. Activated scramblase and inhibited aminophospholipid translocase cause phosphatidylserine exposure in a distinct platelet fraction. Cell Mol Life Sci 2005; 62: 1514-1525.
• 9 Sinauridze EI, Kireev DA, Popenko NY. et al. Platelet microparticle membranes have 50- to 10322-fold higher specific procoagulant activity than activated platelets. Thromb Haemost 2007; 97: 425-434.
• 10 Pereira J, Alfaro G, Goycoolea M. et al. Circulating platelet-derived microparticles in systemic lupus erythematosus. Association with increased thrombin generation and procoagulant state. Thromb Haemost 2006; 95: 94-99.
• 11 Stone MD, Nelsestuen GL. Efficacy of soluble phospholipids in the prothrombinase reaction. Biochemistry 2005; 44: 4037-4041.
• 12 Thiagarajan P, Benedict CR. Inhibition of arterial thrombosis by recombinant annexin V in a rabbit carotid artery injury model. Circulation 1997; 96: 2339-2347.
• 13 Kuypers FA, Larkin SK, Emeis JJ. et al. Interaction of an annexin V homodimer (Diannexin) with phosphatidylserine on cell surfaces and consequent antithrombotic activity. Thromb Haemost 2007; 97: 478-486.
• 14 Dasgupta SK, Guchhait P, Thiagarajan P. Lactadherin binding and phosphatidylserine expression on cell surface-comparison with annexin A5. Transl Res 2006; 148: 19-25.
• 15 Shi J, Gilbert GE. Lactadherin inhibits enzyme complexes of blood coagulation by competing for phospholipid-binding sites. Blood 2003; 101: 2628-2636.
• 16 Shi J, Shi Y, Waehrens L. et al. Lactadherin detects early phosphatidylserine exposure on immortalized leukemia cells undergoing programmed cell death. Cytometry 2006; 69A: 1193-1201.
• 17 Lin L, Huai Q, Huang M. et al. Crystal structure of the bovine lactadherin C2 domain, a membrane binding motif, shows similarity to the C2 domains of factor V and factor VIII. J Mol Biol 2007; epub ahead of print.
• 18 Billy D, Willems GM, Hemker HC. et al. Prothrombin contributes to the assembly of the factor Va-factor Xa complex at phosphatidylserine-containing phospholipid membranes. J Biol Chem 1995; 270: 26883-26889.
• 19 Willems GM, Janssen MP, Pelsers MMAL. et al. Role of divalency in the high-affinity binding of anticardiolipin antibody – β2-glycoprotein I complexes to lipid membranes. Biochemistry 1996; 35: 13833-13842.
• 20 Mayer LD, Hope MJ, Cullis PR. Vesicles of variable sizes produced by a rapid extrusion procedure. Biochim Biophys Acta 1986; 858: 161-168.
• 21 Hemker HC, Giesen P, AlDieri R. et al. The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. Pathophysiol Haemost Thromb 2002; 32: 249-253.
• 22 Smirnov MD, Ford DA, Esmon CT. et al. The effect of membrane composition on the hemostatic balance. Biochemistry 1999; 38: 3591-3598.
• 23 Butenas S, Branda RF, van’t Veer C. et al. Platelets and phospholipids in tissue factor-initiated thrombin generation. Thromb Haemost 2001; 86: 660-667.
• 24 Pieters J, Lindhout T. The limited importance of factor Xa inhibition to the anticoagulant property of heparin in thromboplastin-activated plasma. Blood 1988; 72: 2048-2052.
• 25 Lawson JH, Kalafatis M, Stram S. et al. A model for the tissue factor pathway to thrombin. I. An empirical study. J Biol Chem 1994; 269: 23357-23366.
• 26 Butenas S, van’t Veer C, Mann KG. “Normal” thrombin generation. Blood 1999; 94: 2169-2178.
• 27 Pieters J, Lindhout T, Hemker HC. In situ-generated thrombin is the only enzyme that effectively activates factor VIII and factor V in thromboplastin-activated plasma. Blood 1989; 74: 1021-1024.
• 28 Kastrup CJ, Runyon MK, Shen F. et al. Modular chemical mechanism predicts spatiotemporal dynamics of initiation in the complex network of hemostasis. Proc Natl Acad Sci USA 2006; 103: 15747-15752.
• 29 Liang X, Quinn-Allen MA, Kane WH. Cholesterol and phosphatidylethanolamine enhance the binding of factor Va and factor Xa to phospholipid vesicles and promote assembly of the prothrombinase complex on membranes containing low concentrations of phosphatidylserine. Blood 2006; 108: 1712 (Abstr).
• 30 Nesheim ME, Nichols WL, Cole TL. et al. Isolation and study of an acquired inhibitor of human coagulation factor V. J Clin Invest 1986; 77: 405-415.
• 31 Perdekamp MT, Rubenstein DA, Jesty J. et al. Platelet factor V supports hemostasis in a patient with an acquired factor V inhibitor, as shown by prothrombinase and tenase assays. Blood Coagul Fibrinolysis 2006; 17: 593-597.
• 32 Mosser G, Ravanat C, Freyssinet JM. et al. Sub-domain structure of lipid-bound annexin-V resolved by electron image analysis. J Mol Biol 1991; 217: 241-245.
• 33 Richter RP, Him JL, Tessier B. et al. On the kinetics of adsorption and two-dimensional self-assembly of annexin A5 on supported lipid bilayers. Biophys J 2005; 89: 3372-3385.